Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 10:25pm CET

By a News Reporter-Staff News Editor at Pharma Business Week -- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead's cash tender offer for Kite expired at 11:59 p.m. on September 25, 2017 (see also Biotechnology Companies).

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170926005682/en/

On September 8, 2017, Gilead and Kite filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice.

Keywords for this news article include: Gilead Sciences Inc., Biotechnology Companies, Biopharmaceutical Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
01/19 GILEAD SCIENCES : - Kite Announces Clinical Collaboration to Evaluate Investigat..
01/19 GILEAD SCIENCES : Findings from Gilead Sciences Yields New Findings on HIV/AIDS ..
01/19 GILEAD SCIENCES : Kite Announces Clinical Collaboration to Evaluate Investigatio..
01/18 GILEAD SCIENCES : Kite Announces Clinical Collaboration to Evaluate Investigatio..
01/13 GILEAD SCIENCES : GILD) Holder Continental Advisors LLC Lowered Holding as Share..
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
01/12 Respiratory Syncytial Virus Infections– Unmet Needs in Adult Targeted D..
01/08 $11 billion biotech binge fuels forecasts of 2018 M&A surge
01/07 Teen writes book about how to invest money Stock Whiz
More news
News from SeekingAlpha
01/21 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 20, 2018
01/19 JUNO THERAPEUTICS : What The Celgene Potential Acquisition Foretells
01/19 The Passive/Aggressive Portfolio
01/18 Biotech Forum Daily Digest For January 18th
01/18 ANALYZING THE CAR-T MARKET : What Companies Have Performed Best And Will The Tre..
Financials ($)
Sales 2017 25 847 M
EBIT 2017 15 689 M
Net income 2017 10 481 M
Debt 2017 13 757 M
Yield 2017 2,61%
P/E ratio 2017 10,50
P/E ratio 2018 14,08
EV / Sales 2017 4,62x
EV / Sales 2018 5,28x
Capitalization 106 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 86,5 $
Spread / Average Target 6,8%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES13.04%105 754
VERTEX PHARMACEUTICALS4.76%39 951
REGENERON PHARMACEUTICALS-0.50%39 917
GENMAB10.50%11 762
EXELIXIS, INC.-9.57%8 284
BLUEBIRD BIO INC2.25%8 064